The article presents a study on the pro-inflammatory effect of the drug rapamycin on phagocytic cells. Rapamycin, which is used in preventing graft rejection, blocks the activity of mamalian target of rapamycin (mTOR), increasing the capacity of phagocytic cells to produce cytokines. Other details including results and the inflammatory side effects of rapamycin in transplant recipients are also presented.